In premenopausal o perimenopausal women with advanced HR+, HER2- BC, overall survival was longer with a CDK4/6 inhibitor plus endocrine therapy (including goserelin) than endocrine therapy alone (47, 48). This evidence concerns the gene ERBB2 and breast cancer.